Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

University of Missouri to award honorary degree to Chairman and CEO of Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Dr. Gary S. Jacob, will be recognized and awarded with the honorary degree, Doctor of Science Honoris Causa, from his alma mater, the University of Missouri - St. Louis, at a commencement ceremony this Saturday, May 17, 2014.

15 May 2014

Olympus launches next-generation ENDOCAPSULE 10 System for capsule endoscopy procedures

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products, among other core businesses, announced today the commercial availability of its 510(k) cleared, next-generation ENDOCAPSULE 10 System for small bowel capsule endoscopy procedures.

From Evident Corporation - Life Sciences 5 May 2014

Vibrating oral capsule for chronic constipation shows positive results

An oral capsule that vibrates as it moves through the digestive tract has shown notable promise as a non-pharmacological treatment for constipation, according to new research presented today at Digestive Disease Week- (DDW).

5 May 2014

Synergy reports positive top-line results from plecanatide phase 2b study in patients with IBS-C

Synergy Pharmaceuticals Inc. today announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide's safety and efficacy in 424 patients with irritable bowel syndrome with constipation (IBS-C).

30 Apr 2014

Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories, Inc. nd Furiex Pharmaceuticals, Inc. today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

28 Apr 2014

Reduced exposure to microbes triggers chronic inflammation

The greater prevalence of asthma, allergies and other chronic inflammatory disorders among people of lower socioeconomic status might be due in part to their reduced exposure to the microbes that thrive in rural environments, according to a new scientific paper.

25 Apr 2014

Nearly 179 million cases of acute diarrhea occur each year in the U.S.

In the United States, approximately 179 million cases of acute diarrhea occur each year, and most of those cases are entirely preventable, a researcher from The University of Texas Health Science Center at Houston concluded in a New England Journal of Medicine review article.

23 Apr 2014

Prevalence of celiac disease on the rise among children with irritable bowel syndrome

There appears to be an increased prevalence of celiac disease among children with irritable bowel syndrome (IBS).

22 Apr 2014

Study sheds light on factors that lead to development of rare condition affecting inner ear

A new study has shed light on the factors likely to lead to the development of a rare condition affecting the inner ear.

16 Apr 2014

Sanofi Korea launches gut health product, Probi Digestis

Probi has signed a distribution and supply agreement with Sanofi. Following this the Consumer Healthcare division of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestis starting in April 2014. Probi has already delivered products and received substantial orders for the coming quarters.

15 Apr 2014

Discovery could lead to new therapies for people with celiac disease

Researchers at McMaster University have discovered a key molecule that could lead to new therapies for people with celiac disease, an often painful and currently untreatable autoimmune disorder.

1 Apr 2014

Celiac disease people may have near two-fold increased risk of coronary artery disease

People with celiac disease may have a near two-fold increased risk of coronary artery disease compared with the general population, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session.

31 Mar 2014

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), which means there is chronic inflammation and ulceration in the lining of the digestive tract, usually in the large intestine.

26 Mar 2014

Researchers identify genetic defect that causes a subset of irritable bowel syndrome

Is irritable bowel syndrome (IBS) caused by genetics, diet, past trauma, anxiety? All are thought to play a role, but now, for the first time, researchers have reported a defined genetic defect that causes a subset of IBS. The research was published in the journal Gastroenterology.

21 Mar 2014

Concordia Healthcare enters into definitive agreement to acquire Donnatal

Concordia Healthcare Corp., announced today that it has entered into a definitive agreement to acquire Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS") and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals").

20 Mar 2014

Biologists discover WBC moves to inflamed sites by walking in a stepwise manner

A team of biologists and engineers at the University of California, San Diego has discovered that white blood cells, which repair damaged tissue as part of the body's immune response, move to inflamed sites by walking in a stepwise manner.

19 Mar 2014

Findings suggest that IBS is linked to detectable gut microbiota alterations

Irritable bowel syndrome (IBS) belongs to the most widespread diseases in Western countries, causing up to sixty per cent of the workload of gastrointestinal physicians. One of the most frequent symptoms of IBS is bloating, which reduces quality of life considerably as patients perceive it as particularly bothersome.

10 Mar 2014

Conditioned pain modulation decreases activity in human spinal cord, say researchers

Researchers have demonstrated that conditioned pain modulation (CPM), a measure of the brain's ability to regulate pain, decreases activity in the human spinal cord as visible via functional magnetic resonance imaging (fMRI).

10 Mar 2014

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.

4 Feb 2014

Scientists, clinicians to examine role of human gut microbiota in digestive and overall health

The microbial communities that reside in the human gut and their impact on human health and disease are one of the most exciting new areas of research today. To address the most recent advances in this rapidly developing field, scientists and health-care professionals from all over the world will come together at the Gut Microbiota for Health World Summit in Miami, Florida, on March 8 and 9, 2014.

24 Jan 2014

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

University of Missouri to award honorary degree to Chairman and CEO of Synergy Pharmaceuticals

Olympus launches next-generation ENDOCAPSULE 10 System for capsule endoscopy procedures

Vibrating oral capsule for chronic constipation shows positive results

Synergy reports positive top-line results from plecanatide phase 2b study in patients with IBS-C

Forest Laboratories enters into definitive agreement to acquire Furiex

Reduced exposure to microbes triggers chronic inflammation

Nearly 179 million cases of acute diarrhea occur each year in the U.S.

Prevalence of celiac disease on the rise among children with irritable bowel syndrome

Study sheds light on factors that lead to development of rare condition affecting inner ear

Sanofi Korea launches gut health product, Probi Digestis

Discovery could lead to new therapies for people with celiac disease

Celiac disease people may have near two-fold increased risk of coronary artery disease

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Researchers identify genetic defect that causes a subset of irritable bowel syndrome

Concordia Healthcare enters into definitive agreement to acquire Donnatal

Biologists discover WBC moves to inflamed sites by walking in a stepwise manner

Findings suggest that IBS is linked to detectable gut microbiota alterations

Conditioned pain modulation decreases activity in human spinal cord, say researchers

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Scientists, clinicians to examine role of human gut microbiota in digestive and overall health

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in